New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 14, 2014
07:37 EDTSUPNSupernus receives FDA fast track designation for SPN-810
Supernus Pharmaceuticals announced that the United States Food and Drug Administration has granted fast track designation for SPN-810 for the treatment of impulsive aggression in attention deficit hyperactivity disorder. This product candidate is expected to enter Phase III testing, with patient dosing commencing during 2015.
News For SUPN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 14, 2014
09:08 EDTSUPNSupernus announces Paragraph IV ANDA filing for Trokendi XR
Supernus Pharmaceuticals announced that on October 13, the company received a Paragraph IV Notice Letter from Zydus Pharmaceuticals advising Supernus of the filing by Zydus of an Abbreviated New Drug Application seeking approval for topiramate extended-release capsules. Supernus is currently reviewing the details of this Notice Letter and intends to vigorously enforce its intellectual property rights relating to Trokendi XR. The product is currently protected by three issued patents that are listed in the FDA's Orange Book and expire no earlier than 2027.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use